Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Shares Issued (2021 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Shares Issued for 6 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued rose 93.81% year-over-year to $2.4 million, compared with a TTM value of $11.6 million through Dec 2025, up 830.71%, and an annual FY2025 reading of $11.6 million, up 830.71% over the prior year.
  • Shares Issued was $2.4 million for Q4 2025 at Xeris Biopharma Holdings, down from $8.3 million in the prior quarter.
  • Across five years, Shares Issued topped out at $29.5 million in Q3 2022 and bottomed at -$30.0 million in Q4 2022.
  • Average Shares Issued over 5 years is $824764.7, with a median of $475000.0 recorded in 2021.
  • Peak annual rise in Shares Issued hit 14346.38% in 2022, while the deepest fall reached 6414.11% in 2022.
  • Year by year, Shares Issued stood at $475000.0 in 2021, then plummeted by 6414.11% to -$30.0 million in 2022, then skyrocketed by 101.72% to $517000.0 in 2023, then skyrocketed by 140.62% to $1.2 million in 2024, then skyrocketed by 93.81% to $2.4 million in 2025.
  • Business Quant data shows Shares Issued for XERS at $2.4 million in Q4 2025, $8.3 million in Q3 2025, and -$4.0 million in Q2 2025.